Physician profile
Christine Ablett
NPI 1134452832
$1,316.57
in general payments reported to CMS, 2019-2025
27 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what 88% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $16.61 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.17 |
| Education | $188.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $180.41 | 2025 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $178.34 | 2025 | Enhertu, Calquence |
| Daiichi Sankyo INC. | $145.39 | 2025 | Enhertu, Datroway, Injectafer |
| Astellas Pharma US INC | $107.13 | 2025 | Padcev |
| Pharmacosmos Therapeutics INC. | $76.56 | 2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $72.58 | 2025 | |
| Celgene Corporation | $54.41 | 2025 | Reblozyl |
| Tersera Therapeutics LLC | $53.99 | 2025 | Zoladex |
| Gilead Sciences, INC. | $45.39 | 2025 | Trodelvy |
| Novocure INC. | $40.99 | 2025 | Optune Gio |
| Merck Sharp & Dohme LLC | $36.92 | 2025 | Keytruda, Welireg |
| Pharmaessentia USA Corporation | $35.69 | 2025 | Besremi |
| Geron Corporation | $34.09 | 2025 | Rytelo |
| Janssen Biotech, INC. | $32.51 | 2025 | Tecvayli, Darzalex |
| Alexion Pharmaceuticals, INC. | $21.21 | 2025 | Ultomiris |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $19.95 | 2025 | |
| Sobi, INC | $19.56 | 2025 | |
| Genentech USA, INC. | $18.75 | 2025 | Polivy |
| Lilly USA, LLC | $18.52 | 2025 | Verzenio, Jaypirca |
| Servier Pharmaceuticals LLC | $17.66 | 2025 | |
| Genmab U.S., INC. | $16.96 | 2025 | Tivdak |
| Corcept Therapeutics | $16.61 | 2024 | Korlym |
| Dendreon Pharmaceuticals LLC | $16.18 | 2025 | Provenge |
| Springworks Therapeutics, INC. | $15.76 | 2025 | Ogsiveo |
| E.R. Squibb & Sons, L.L.C. | $15.48 | 2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $14.85 | 2025 | |
| Iovance Biotherapeutics, INC. | $10.68 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Ablett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.